Skip to main content
Premium Trial:

Request an Annual Quote

Applied Markets Watch: IntegenX RapidHit DNA Identification System


IntegenX said this week that it has completed developmental validation for its RapidHit System, a fully automated and integrated rapid human DNA identification system.

The company presented data from the validation study this week at the World Congress of the International Society of Forensic Genetics in Melbourne, Australia.

Completion of Scientific Working Group for DNA Analysis Methods, or SWGDAM, developmental validation is a key milestone necessary for the full commercialization of DNA technologies for human identification in forensics, law enforcement, defense, homeland security, and intelligence, IntegenX said.

In addition to developmental validation data, the company will present data on the use of RapidHit to analyze samples routinely recovered from crime scenes, such as blood or saliva.

IntegenX introduced the RapidHit system at the International Association of Chiefs of Police Conference and Law Enforcement Education and Technology Exposition in San Diego last October (PCR Insider, 10/4/2012). The system fully automates and integrates all necessary steps — including bead-based cell lysis, DNA purification, and industry-standard amplification using a Promega kit — to generate a DNA profile in approximately 90 minutes, IntegenX said. With less than five minutes of hands-on time, users can generate up to five complete DNA profiles, as well as a positive and negative control. Generated profiles are compatible with standard databases containing previous profiles from reference and crime scene sources.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.